Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kummar Website

Shivaani Kummar, M.D., F.A.C.P.

Portait Photo of Shivaani Kummar
Developmental Therapeutics Branch
Head, Developmental Therapeutics Clinic
Adjunct Staff Clinician
Center for Cancer Research
National Cancer Institute
Building 31, Room 3A44
Bethesda, MD 20892


Dr. Kummar received her medical degree from Lady Hardinge Medical College, New Delhi, India, and her internal medicine residency training from Emory University, Atlanta, GA. Upon completion of her fellowship training in medical oncology and hematology from the National Institutes of Health, Bethesda, Maryland, she joined Yale Cancer Center, Yale University, New Haven, CT, as an assistant professor in medical oncology. In 2004, Dr. Kummar moved back to NCI and is currently head of the Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute. Her research interests focus on the early development (Phase I/II trials) of novel therapies for cancer.


Dr Kummar's clinical interests focus on early drug development in Cancer. She is the Principal Investigator of over 30 clinical protocols including the first Phase 0 trial in Oncology conducted by the NCI. She has published in major peer-reviewed journals in the field of oncology. Dr Kummar serves of the scientific program committee for the American Society of Clinical Oncology (ASCO) annual meetigns and is a member of ASCO and the American Association for Cancer Research (AACR).

Selected publications:
Book Chapters:
1. A. Book Chapters:

1. Kummar S, Anthony J. Murgo, Joseph E. Tomaszewski, James H. Doroshow. Therapeutic Targeting of Cancer Cells. Chapter 28, Abeloff's Clinical Oncology, 5th edition; 2012

2. Kummar S, Harris P, Ivy P. Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers and suggestions for future trials. Handbook of Anticancer Agents Pharmacokinetics and Pharmacodynamics, Second Edition (in press).

3. Kummar S, Doroshow JH. Phase 0 trials in Oncology. Handbook of Anticancer Agents Pharmacokinetics and Pharmacodynamics, Second Edition (in press).

4. Kummar S, Doroshow JH. Role of Phase 0 Trials in Cancer Drug Development. Recent Advances in Clinical Research, Third Edition 2011.

5. Murgo AJ, Kummar S, Gutierrez M, Tomaszewski JE, Doroshow JH. Principles of Molecularly Targeted Therapy: Present and Future. Clinical Oncology (Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG); 4th Edition, 2009.

6. Kummar S, Noronha V, Chu E. Antimetabolites. Cancer Principles and Practice of Oncology (Devita VT, Hellman S, Rosenberg SA); 7th Edition, 2004.

Journal publications:
1. Do K, Doroshow JH, Kummar S. Antiangiogenic approaches for the treatment of advanced synovial sarcomas. Curr Opin Oncol. 2012; May 8. [Epub ahead of print]

2. Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in Using PARP Inhibitors to treat cancer. BMC Med. 2012;10(1):25.

3. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara D, Allen D, Kiesel B, Beumer JH, Newman E, Rubinstein L, Chen A, Zhang Y, Wand L, Kinders R, Parchment RE, Tomaszewski JE, Doroshow JH. A Phase I Study Of Veliparib In Combination with Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors And Lymphomas. Clin Can Res 2012; Feb 3. [Epub ahead of print]

4. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel JD, Venzon D, Dahut B, Kohn EC, Kummar S, Yarchoan R, Giaccone G, Widemann BC, Figg WD. Sorafenib is an Inhibitor of UGT1A1 but is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. Clin Can Res 2012; Feb 3. [Epub ahead of print]

5. Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle. 2011;10(23): 4074-82.

6. Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tmaszewski JE, Doroshow JH. Modeling Pharmacodynamic Response to the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells. PLoS One. 2011;6(10):e26152.

7. Rajan A, Kelly RJ, Trepel JB, Yim YS, Alacron SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannagudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G. A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Clin Can Res 2011; 17(21):6831-9.

8. Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O’Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E. A Phase I Sudy of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer. Clin Colorectal Cancer 2011;10(2):85-96.

9. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH. Phase I study of PARP inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Can Res 2011;71(17):5626-34.

10. Speranza G, Gutierrez M, Kummar S, Strong J, Parker R, Collins J, Yu Y, Cao L, Murgo A, Doroshow JH, Chen A. Phase I Study of the Synthetic Triterpenoid, 2-Cyano-3, 12-Dioxoolean-1, 9-Dien-28-Oic Acid (CDDO), in Advanced Solid Tumors. Cancer Chemother Pharmacol 2012; 69(2):431-8. (EPub Jul 31, 2011)

11. Argiris A, Duffy A, Kummar S, Simone NL, Arai Y, Kim S, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 2011;17(17):5755-64.

12. Kummar S, Raffeld M, Juwara L, Horneffer YR, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey B, Choyke PL, Murgo AJ, Doroshow JH, Melillo G. Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1{alpha} (HIF-1{alpha}) in Advanced Solid Tumors. Clin Cancer Res 2011; 17(15):5123-31.

13. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD. Population pharmacokinetic analysis of sorafenib in patients with solid tumors. Br J Clin Pharmacol 2011; 72(2):294-305.

14. Kummar S, Doroshow JH. Phase 0 Trials: Expediting the Development of Chemoprevention Agents. Cancer Prev Res 2011; 4(3):288-92.

15. Kummar S. Foreword: Poly (ADP-ribose) polymerase inhibitors in clinical development. Curr Probl Cancer 2011; 35(1):6.

16. Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH. Phase I Trial of Vandetanib and Bevacizumab Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumours and Lymphomas. Eur J Cancer 2011; 47(7):997-1005.
17. Kummar S, Gutierrez ME, Maurer BJ, Reynolds P, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH. Phase I Trial of Fenretinide Lym-X-Sorb Oral Powder in Adults With Solid Tumors and Lymphomas. Anticancer Research 2011; 31(3):961-6.
18. Kelly R, Rajan A, Force J, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg S, Wright J, Lopez-Chavez A, Kummar S, Gutierrez M, Giaccone G. Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib. Clin Cancer Res 2011; 17(5):1190-9.

19. Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zwiebel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov. 2010;9(11):843-56.

20. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Harvey RD, Yerk M, Holleran J, Lin Y, Beumer JH, Ivy SP, Belani CP, Egorin MJ. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group (ODWG) study. J Clin Oncol. 2010;28(29):4507-12.

21. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 14(29):95

22. Speranza G, Doroshow JH, Kummar S. Adenocarcinoma of the small bowel: changes in the landscape? Curr Opin Oncol. 2010; 22(4):387-93.
23. Rubinstein L, Steinberg S, Kummar S, Kinders R, Parchment R, Murgo AJ, Tomaszewski JE, Doroshow JH. The statistics of Phase ‘0’ trials. Stats Med. 2010; 29(10):1072-6.

24. Kummar S. Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword. Curr Probl Cancer. 2010;34(2):130.

25. Kurkjian C, Kummar S, Stewart D, Waxman K, Lam A, Shah S, Paparello J, Katz WA, Barkin RL. Topics in clinical pharmacology: renal, gastrointestinal, and pain management. Dis Mon 2010;56(4):187-250.

26. Wang L, Pfister T, Parchment R, Kummar S, Evrard Y, Gutierrez M, Murgo A, Tomaszewski JE, Dorohsow JH. Monitoring Drug-Induced gammaH2AX Changes as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells. Clin Cancer Res. 2010;16(3):1073-84.

27. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg W, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey M, Horneffer Y, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ. Phase I Trial of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG), a Heat Shock Protein Inhibitor, Administered Twice Weekly in Patients with Advanced Malignancies. Eur J Cancer. 2010; 46(2):340-7.

28. Kummar S, Gutierrez ME, Gardner ER, Figg W, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH. A Phase I Trial of UCN-01 and Prednisone in Patients With Refractory Solid Tumors and Lymphomas. Cancer Chemother Pharmacol. 2010; 65(2):383-9.

29. Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther. 2009;16(5):412-20.

30. Kummar S, Malhotra SV. Cancer drug development in India. Nature India 2009 (Epub December 23, 2009)
31. Duffy A, Kummar S. Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Target Oncol. 2009; 4(4):267-73.

32. Yang S, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH, NCI Phase 0 Working Group. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther. 2009; 8(21):2004-9.

33. Kummar S, Doroshow JH. Phase ‘0’ clinical trials. Fut Med Chem. 2009; 1(8):1375-1380.

34. Duffy A, Kummar S. Metastatic pancreatic adenocarcinoma: current standards, future directions. Am J Ther. 2009; 17(1):79-85.
35. Kummar S. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Foreword. Curr Probl Cancer. 2009;33(2):72.

36. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol. 2009;6(5):259-65 .

37. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705-11.

38. Kummar S. Multiple Myeloma. Foreword. Curr Probl Cancer. 2009;33(1):6.

39. Kummar S, Doroshow JH, Murgo A. Why close collaboration between bench scientists and clinicians is crucial to phase 0 trial design and
conduct. Good Clin Prac J. 2009.

40. Kummar S, Doroshow JH, Tomaszewski JE, Calvert HA, Lobbezoo M, Giaccone G. Phase 0 clinical trials: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer. 2009; 45(5):741-6.

41. Kummar S, Kurkjian C. Advances in the treatment of metastatic colorectal cancer. Am J Ther. 2009; 16(5):412-20.

42. Kurkjian C, Murgo AJ, Kummar S. Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy. Clin Colorectal Cancer. 2008;7(5):321-4.

43. Kurkjian C, Kummar S, Murgo AJ. DNA Methylation: Its role in cancer development and therapy. Curr Probl Cancer. 2008;32(5):187-235.

44. Kurkjian C, Kummar S, Murgo AJ. The observation that changes in DNA methylation potentially play a role in neoplastic transformation has existed for nearly 30 years. Foreword. Curr Probl Cancer. 2008;32(5):185-6.

45. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol. 2008;20(6):639-49.

46. Kurkjian C, Murgo AJ, Kummar S. Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy. Clin Colorectal Cancer. 2008;7(5):321-4.

47. Kummar S: The mammalian target of rapamycin (mTOR). Foreword. Curr Probl Cancer.2008;32(4):160.

48. Chen T, Lee MJ, Kim YS, Lee S, Kummar S, Gutierrez M, Hewitt SM, Trepel JB, Levin IW. Pharmacodynamic Assessment of Histone Deacetylase Inhibitors: Infrared Vibrational Spectroscopic Imaging of Protein Acetylation. Anal Chem. 2008; 80(16):6390-96.

49. Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Designing Phase 0 Cancer Clinical Trials. Clin Cancer Res. 2008;14(12):3675-82.

50. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH. Phase 0 Clinical Trials: Conceptions and Misconceptions. Cancer J. 2008;14(3):133-7.

51. Donovan EA, Kummar S. Role of Insulin-like Growth Factor-1R System in Colorectal Carcinogenesis. Crit Rev Oncol Hematol. 2008;66(2):91-8.

52. Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv. 2007;7(6):325-34.

53. Lee M-J, Chung EJ, Lee S, Chung J-Y, Telford WG, Sausville EA, Gojo I, Karp JE, Gore SD, Kapoor V, Kim YS, Kummar S, Gutierrez M, Hewitt SM, Trepel JB. A cell microarray platform for anticancer drug development. Drug Dev Res. 2007;68:226-34.

54. Chen X, Gardner ER, Gutierrez M, Kummar S, Figg WD. Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858(1-2):302-6.

55. Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18):5411-17.

56. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer. 2007;7(2):131-9.

57. Donovan EA, Kim YS, Trepel JB, Kummar S. The use of histone deacetylase inhibitors for the treatment of solid tumors. Touch Briefings: US Oncological Disease 2007, issue II:12-16.

58. Conley, BA, Wright, JJ, Kummar, S. Targeting Epigenetic Abnormalities with Histone Deacetylase Inhibitors. Cancer 2006;107(4):832-40.

59. Kummar S, Gutierrez ME, Doroshow JH, Murgo A. Drug Development in Oncology: Classical Cytotoxics and Molecularly Targeted Agents. Br J Clin Pharmacol. 2006; 62(1):15-26.

60. Donovan E, Kummar S. Targeting VEGF in cancer therapy. Curr Probl Cancer. 2006;30(1):7-32.

61. Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD, Sparreboom A. Determination of the heat shock protein 90 inhibitor 17-dimethylamino-ethylamino-17-demethoxygeldanamycin (17-DMAG) in plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;830(1):35-40.

62. O’Mahony D, Kummar S, Gutierrez, M. Non-Small Cell Lung Cancer Vaccine Therapy: A concise review. J Clin Oncol. 2005;23(35):9022-8.

63. Sportès C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE. Establishing A Platform For Immunotherapy: Clinical Outcome and Study of Immune Reconstitution Following High-Dose Chemotherapy With Progenitor Cell Support in Breast Cancer Patients. Biol Blood Marrow Transplant 2005;11(6):472-83.
64. Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin’s Lymphoma of the Liver. Crit Rev Oncol Hematol. 2005; 53(3):199-207.

65. Kummar S, Shafi NQ. False Elevations in Prostate Specific Antigen Levels Affecting Patient Management. Clin Adv Hematol Oncol. 2004; 2(9): 599-601.

66. Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M. A Phase I and Pharmacokinetic Study of VNP40101M, a New Alkylating Agent, in Patients with Advanced or Metastatic Cancer. Invest New Drugs. 2005 Jan;23(2):123-35.

67. Kummar S: Small Bowel Adenocarcinoma, A Commentary. Clin Colon Cancer. 2004;4(4):249-51.

68. Hobdy E, Shafi NQ, Kummar S. Prostate Cancer Metastasis Involving the Supraclavicular Node. Clin Adv Hematol Oncol. 2004;2(4):223-4.

69. Farrell MP, Kummar S: Phase I/IIA Randomized Study of PHY906, a Novel Herbal Agent, as a Modulator of Chemotherapy in Patients with Advanced Colorectal Cancer. Clin Colorectal Cancer. 2003;2(4):253-6.

70. Hobdy E, Ciesielski TE, Kummar S. Unusual Sites of Colorectal Cancer Metastasis. Clin Colorectal Cancer. 2003;3(1):54-7.

71. Kummar S, Shafi NQ: Metastatic Hepatocellulcar Carcinoma-A Case Report and Review. Clinical Oncology. 2003;15:288-94.

72. Kummar S, Ciesielski TE, Fogarasi MC: Management of Small Bowel Adenocarcinoma. Oncology (Williston Park). 2002; 1610:1364-9.

73. Kummar S, Fogarasi M, Canova A, Mota A, Cieselski T: Cytokeratin 7 and 20 Staining for the Diagnosis of Lung and Colorectal Adenocarcinomas. Br J Cancer. 2002;86(12):1884-7.

74. Kummar S, Ciesielski TE: Cytokeratin Staining for Primary and Metastatic Colorectal Cancer. Clin Colon Cancer. 2001;1(3):187-8.

75. Fogarasi MC, Zelkowitz RS, Messana SA, Arrighi JA, Kummar S: Positron Emission Tomography for the Evaluation of Patients with Colorectal Cancer. Clin Colon Cancer. 2001;1(2):117-20.

76. Kummar S, Ishii A,Yang H, Venzon DJ, Kim S, Gress RE: Modulation of Graft Versus Tumor Effects in a Murine Allogeneic BMT Model by Tumor Derived Transforming Growth Factor-(TGF-1). Biol Blood Marrow Transplant 2001;7:25-30.

77. Kummar S, Kim S, Halkar RK, Galt JR: In-111 labeled Octreotide Imaging of a Primary Carcinoid Lesion Undetected by Conventional Imaging Studies in a patient with 'Chronic Pancreatitis'. Clin Nucl Med. 1996; 21:634-7.

This page was last updated on 6/4/2014.